Reviewer’s report

Title: Reduced Frequency of Intravitreal Methotrexate Lowers the Risk of Keratopathy in Vitreoretinal Lymphoma Patients

Version: 0 Date: 16 Feb 2020

Reviewer: Yoshihiko Usui

Reviewer’s report:

Overall, the manuscript is clearly written and represents some contribution to the field. Although the methodology was apparently properly used and I agree with the potential value of this work, the limited sample size diminish my enthusiasm for this work. And, I also agree with that the optimal treatment for intraocular lymphoma is not yet determined. Coupled with the disappointingly low number of subjects, it is highly likely that your findings are spurious.

1. The authors should change intraocular lymphoma to vitreoretinal lymphoma.
2. What is the study type? Looks like case-control or comparative method evaluation, but this is never explicitly stated.
3. How many were rejected, how many were excluded?
4. How many patients have been done radiation before intravitreal MTX injection. Radiation higher the risk of keratopathy in vitreoretinal lymphoma patients.
5. Why are the groups not of equal size? The manuscript is not clear here.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal